BETd-260 NEW
| Price | $132 | $328 | $496 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BETd-260 | CAS No.: 2093388-62-4 |
| Purity: 96.76% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BETd-260 |
| Description | BETd-260, a PROTAC linked by a Cereblon ligand and a BET ligand, has an inhibitory effect on BRD4 protein in leukemic cell lines. |
| In vitro | betd - 260 (ZBC260; Compound 23) induced the degradation of BRD2, BRD3 and BRD4 proteins. BETd-260 acted on RS4; The ic50 measured for 11 leukemic cells was 51 pM. The ic50 of BETd-260 in MOLM-13 cells was 2.2 nM. BETd-260 at 3-10 nM could induce RS4; 11 and MOLM-13 cell apoptosis. Moreover, BETd-260 inhibited the transcription and translation of anti-apoptotic genes Mcl-1, Bcl-2, c-Myc and XIAP and increased the transcription and translation of pro-apoptotic gene Bad in HCC cells[1]. |
| In vivo | BETd-260, administered intravenously at a dosage of 5 mg/kg, effectively degrades the proteins BRD2, BRD3, and BRD4, maintaining this activity for over 24 hours. This process is accompanied by significant PARP and caspase-3 cleavage, along with a marked reduction in c-Myc protein levels in the RS4;11 xenograft mouse model[1]. When administered bi-weekly, three times a week for three weeks, BETd-260 induces rapid tumor regression, achieving a peak regression greater than 90% in RS4;11 xenograft tumor-bearing mice. Notably, this treatment regimen does not lead to weight loss or other toxicity symptoms in the mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 22.5 mg/mL (28.2 mM), Sonication is recommended. H2O : 0.1 mg/mL, insoluble |
| Keywords | BETd-260 | ZBC260 | ZBC-260 |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | ARV-471 | Curcumin | dBET6 | Naphthol AS-E | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $6.00/1KG |
VIP1Y
|
Hebei Longbang Technology Co., Ltd
|
2024-05-28 | |
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1mg |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-08-26 | |
| $132.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY